Transplant Genomics
Brookline, US · Founded 2013 · Delaware corporation
Transplant Genomics develops non-invasive molecular diagnostic tests to detect early signs of graft rejection and injury in kidney and liver transplant patients, helping clinicians optimize immunosuppressive therapy and avoid painful biopsies. The company serves transplant centers and clinicians worldwide.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$20.6M disclosed across 7 rounds · 2014–2018
▶$8MraisedSep 2018 · 31 investors · Other Health CareRule 506(b)
▶$8MraisedSep 2018 · 31 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Darren LeeExecutive Officer
- Stanley RoseExecutive Officer, Director
- Roy FirstExecutive Officer
- Jay VenkatesanDirector
- David KravitzDirector
- Chris O'ConnorDirector
- Michael AbecassisDirector
- Peter LewisExecutive Officer
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $200K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3.2MraisedApr 2017 · 27 investors · OtherRule 506(b)
▶$3.2MraisedApr 2017 · 27 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jay VenkatesanDirector
- Michael AbecassisDirector
- Chris O'ConnorDirector
- Stanley RoseExecutive Officer, Director
- Darren LeeExecutive Officer
- Peter LewisExecutive Officer
- Roy FirstExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $3.2M
- Finders' fees
- $31.5K
- Placement agents
- Arcadia Securities, LLC
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$1.7MraisedFeb 2017 · 22 investors · OtherRule 506(b)
▶$1.7MraisedFeb 2017 · 22 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Darren LeeExecutive Officer
- Michael AbecassisDirector
- Peter LewisExecutive Officer
- Roy FirstExecutive Officer
- Stanley RoseExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $1.7M
- Finders' fees
- $21.7K
- Placement agents
- Arcadia Securities, LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$530KraisedMay 2016 · 8 investors · OtherRule 506(b)
▶$530KraisedMay 2016 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Roy FirstExecutive Officer
- Dierdre PierryExecutive Officer
- Brett JensenExecutive Officer
- Michael AbecassisDirector
- Stanley RoseExecutive Officer, Director
- Kyle HartExecutive Officer
- Daniel SalomonDirector
- Darren LeeExecutive Officer
- Offering amount
- $1M
- Amount sold
- $530K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$1.2MraisedOct 2015 · 12 investors · BiotechnologyRule 506(b)
▶$1.2MraisedOct 2015 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyle HartExecutive Officer
- Darren LeeExecutive Officer
- Michael AbecassisDirector
- Dierdre PierryExecutive Officer
- Stanley RoseExecutive Officer, Director
- Daniel SalomonDirector
- Roy FirstExecutive Officer
- Brett JensenExecutive Officer
- Offering amount
- $3M
- Amount sold
- $1.2M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3.2MraisedMay 2015 · 47 investors · OtherRule 506(b)
▶$3.2MraisedMay 2015 · 47 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Daniel SolomonDirector
- Michael AbecassisDirector
- Stanley RoseExecutive Officer, Director
- Offering amount
- $3.2M
- Amount sold
- $3.2M
- Minimum investment
- $6.3K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2.8MraisedApr 2014 · 33 investors · BiotechnologyRule 506(b)
▶$2.8MraisedApr 2014 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanley RoseExecutive Officer, Director
- Michael AbecassisDirector
- Daniel SalomonDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- Minimum investment
- $5K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 05, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
UPMC64 shared keywordsUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
CareDx43 shared keywordsCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
Companies competing with Transplant Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Transplant Genomics do?
- Transplant Genomics develops non-invasive molecular diagnostic tests to detect early signs of graft rejection and injury in kidney and liver transplant patients, helping clinicians optimize immunosuppressive therapy and avoid painful biopsies. The company serves transplant centers and clinicians worldwide.
- How much funding has Transplant Genomics raised?
- Transplant Genomics has disclosed $20.6M raised across 7 rounds.
- Where is Transplant Genomics headquartered?
- Transplant Genomics is headquartered in Brookline, US.